Last reviewed · How we verify
RANCAD
RANCAD is a recombinant human anti-CTLA-4 monoclonal antibody that blocks the inhibitory checkpoint protein CTLA-4 to enhance anti-tumor immune responses.
RANCAD is a recombinant human anti-CTLA-4 monoclonal antibody that blocks the inhibitory checkpoint protein CTLA-4 to enhance anti-tumor immune responses. Used for Advanced or metastatic melanoma, Other solid tumors (under investigation in Phase 3).
At a glance
| Generic name | RANCAD |
|---|---|
| Also known as | RNTA06 |
| Sponsor | TSH Biopharm Corporation Limited |
| Drug class | CTLA-4 inhibitor |
| Target | CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CTLA-4 is an immune checkpoint receptor that suppresses T cell activation and proliferation. By blocking CTLA-4, RANCAD removes this inhibitory signal, allowing T cells to become more activated and mount a stronger anti-tumor immune response. This mechanism is similar to other approved checkpoint inhibitors and is designed to enhance the body's natural anti-cancer immunity.
Approved indications
- Advanced or metastatic melanoma
- Other solid tumors (under investigation in Phase 3)
Common side effects
- Immune-related colitis
- Immune-related hepatitis
- Immune-related pneumonitis
- Fatigue
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RANCAD CI brief — competitive landscape report
- RANCAD updates RSS · CI watch RSS
- TSH Biopharm Corporation Limited portfolio CI